SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been included in Australian guidelines for years, but their place in therapy has evolved as recent evidence demonstrates secondary prevention benefits for cardiovascular disease (CVD) and chronic kidney disease (CKD) irrespective of glycated hemoglobin [6-11].